/PRNewswire/ ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, and NecstGen, a CDMO and centre.
/PRNewswire/ ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, and NecstGen, a CDMO and centre.
/PRNewswire/ ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, and NecstGen, a CDMO and centre.
ProteoNic and NecstGen establish partnership to improve viral vector manufacturing efficiency for Gene Therapies finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Rapid developments in cell and gene therapy in research and industry provide remedies to increasingly more patients while offering the potential to decrease the burden on society. NecstGen was founded to support clinicians, academic groups, and small industrial therapy developers globally to bring cell and gene therapies to patients. The collaboration with Cytiva is intended to give clients access to scalable and flexible solutions.